A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma

Full Title

An Open-Label, First in Human, Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 in Adult Subjects With Relapsed/Refractory B-cell and T-cell Lymphomas

Purpose

Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:

• Peripheral T-cell lymphoma
• Cutaneous T-cell lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Follicular lymphoma
• Diffuse large B-cell lymphoma

STP938 blocks a protein called CTPS1, which plays a role in cancer cell growth. By blocking CTPS1, STP938 may help slow or stop the growth of your cancer. STP938 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have B-cell or T-cell lymphoma that keeps growing even after at least 2 regimens of treatment.
• Have recovered from the serious side effects of prior therapies before taking STP938.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Robert Stuver’s office at 646-608-4308.